BCC patients with BCC-associated STR somatic mutations in BRAF or APC show more marked overexpression of the VEGF signaling pathway (see Figure 11), and so they may be better candidates for potential use of drugs targeting VEGF like bevacizumab, ranibizumab, aflivercept, ramucirumab, or multi-kinase inhibitors like sorafenib or sunitinib. This evidence concerns the gene BRAF and skin basal cell carcinoma.